相关实验视频

Updated: Jun 4, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

对STK11和KEAP1突变在先进NSCLC中测试价值的临床观点

Michelle Shiller¹, Melissa Johnson², Robert Auber³

¹Department of Pathology, Baylor University Medical Center, Dallas, TX, United States.

Frontiers in oncology

|December 20, 2024

概括

转移性非小细胞肺癌 (mNSCLC) 患有STK11或KEAP1突变的患者通常会抵抗标准疗法. 新的数据和临床见解对于为这一具有挑战性的患者群体开发有效治疗至关重要.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
免疫治疗是一种免疫疗法.

背景情况:

转移性非小细胞肺癌 (mNSCLC) 的标准一线治疗包括免疫检查点抑制剂 (ICI) +/-化疗.
显著的mNSCLC患者 (20-30%) 的一个小组表现出对ICI的初级耐药性.
在STK11和KEAP1基因的突变与侵略性的mNSCLC和对ICI的耐药性有关.

研究的目的:

提出关于STK11和KEAP1突变在大量mNSCLC患者队列中的流行率的新数据.
讨论使用当前生物标志物测试检测STK11和KEAP1突变的实际方面.
分享管理STK11或KEAP1突变的mNSCLC患者的临床经验.

主要方法:

在大型临床mNSCLC群体中分析突变患病率.
对STK11和KEAP1.1的生物标记测试方法的审查.
对受影响患者的临床管理策略的回顾性分析.

主要成果:

在mNSCLC中STK11和KEAP1突变的详细流行数据.
讨论这些突变的分子测试的可行性和挑战.
了解STK11/KEAP1突变患者的治疗结果和管理方法.

结论:

由于ICI耐药性,STK11和KEAP1突变在mNSCLC治疗中构成了重大挑战.
准确和可访问的生物标志物测试对于识别这些患者至关重要.
对于这种难以治疗的人群,迫切需要进一步的研究和新的治疗策略.

关键词:

c 原型瘤基因蛋白质 p21 ((ras)这种癌症是癌症癌症.免疫疗法免疫疗法类似鱼的ECH相关蛋白 1 1 非小细胞肺的非小细胞肺蛋白质氨酸-氨酸三氨酸激酶.

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...